Bruker Corporation (NASDAQ:BRKR) Receives Consensus Recommendation of “Hold” from Analysts

Shares of Bruker Corporation (NASDAQ:BRKR) have earned an average recommendation of “Hold” from the fourteen ratings firms that are currently covering the firm, MarketBeat.com reports. Two investment analysts have rated the stock with a sell recommendation, five have assigned a hold recommendation, six have issued a buy recommendation and one has assigned a strong buy recommendation to the company. The average twelve-month price objective among brokers that have updated their coverage on the stock in the last year is $57.00.

A number of brokerages have commented on BRKR. Weiss Ratings reaffirmed a “sell (d+)” rating on shares of Bruker in a research report on Monday, August 31st. UBS Group began coverage on Bruker in a research note on Wednesday, September 9th. They issued a “neutral” rating and a $65.00 price objective for the company. Leerink Partners lifted their target price on Bruker from $60.00 to $70.00 and gave the stock an “outperform” rating in a report on Tuesday, July 7th. Barclays increased their price target on shares of Bruker from $53.00 to $60.00 and gave the stock an “overweight” rating in a report on Wednesday, June 24th. Finally, Citigroup decreased their price objective on shares of Bruker from $60.00 to $53.00 and set a “hold” rating for the company in a research note on Wednesday, August 5th.

Bruker Stock Performance

BRKR opened at $61.39 on Monday. The company has a market cap of $9.35 billion, a P/E ratio of -87.70, a price-to-earnings-growth ratio of 1.93 and a beta of 1.26. The company has a quick ratio of 0.92, a current ratio of 1.85 and a debt-to-equity ratio of 0.76. The firm’s 50-day moving average price is $58.17 and its 200-day moving average price is $49.90. Bruker has a 52-week low of $30.09 and a 52-week high of $65.30.

Bruker (NASDAQ:BRKR) last released its earnings results on Tuesday, August 4th. The medical research company reported $0.49 EPS for the quarter, topping analysts’ consensus estimates of $0.38 by $0.11. The company had revenue of $838.50 million during the quarter, compared to analysts’ expectations of $853.57 million. Bruker had a negative net margin of 2.35% and a positive return on equity of 12.47%. Bruker’s revenue for the quarter was up 5.2% on a year-over-year basis. During the same period last year, the business earned $0.32 EPS. Bruker has set its FY 2026 guidance at 2.100-2.150 EPS. As a group, equities analysts anticipate that Bruker will post 2.12 EPS for the current fiscal year.

Bruker Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Wednesday, October 7th. Investors of record on Monday, September 21st will be issued a $0.05 dividend. This represents a $0.20 annualized dividend and a yield of 0.3%. The ex-dividend date of this dividend is Monday, September 21st. Bruker’s payout ratio is presently -28.57%.

Insider Activity at Bruker

In other Bruker news, VP Mark Munch sold 2,000 shares of the firm’s stock in a transaction that occurred on Tuesday, September 15th. The shares were sold at an average price of $52.87, for a total value of $105,740.00. Following the transaction, the vice president directly owned 134,806 shares of the company’s stock, valued at $7,127,193.22. This trade represents a 1.46% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. 27.20% of the stock is owned by insiders.

Institutional Trading of Bruker

A number of institutional investors and hedge funds have recently added to or reduced their stakes in BRKR. Essential Partners LLC purchased a new position in shares of Bruker in the 1st quarter valued at about $36,000. Global Retirement Partners LLC purchased a new position in Bruker in the second quarter worth approximately $38,000. EverSource Wealth Advisors LLC grew its holdings in Bruker by 532.9% during the 1st quarter. EverSource Wealth Advisors LLC now owns 1,500 shares of the medical research company’s stock worth $54,000 after acquiring an additional 1,263 shares in the last quarter. FNY Investment Advisers LLC purchased a new stake in shares of Bruker in the 2nd quarter valued at approximately $60,000. Finally, IFP Advisors Inc increased its position in shares of Bruker by 88.6% in the 2nd quarter. IFP Advisors Inc now owns 1,060 shares of the medical research company’s stock valued at $64,000 after purchasing an additional 498 shares during the last quarter. Hedge funds and other institutional investors own 79.52% of the company’s stock.

About Bruker

Bruker Corporation develops and manufactures scientific instruments, analytical systems and software used to study the chemical, physical and biological properties of materials. Its customers include universities, pharmaceutical and biotechnology companies, industrial manufacturers, hospitals, government laboratories and other research organizations.

The company’s product portfolio includes nuclear magnetic resonance and electron paramagnetic resonance systems, mass spectrometers, X-ray analysis instruments, optical and molecular spectroscopy systems, microscopy and nanoanalysis tools, and instruments for microbiology and spatial biology.